The future of vaccine research

The COVID-19 pandemic accelerated the development of novel platforms like mRNA vaccines, showcasing the potential for rapid innovation. However, despite these breakthroughs, significant challenges remain in vaccine research, including preclinical model limitations, immune variability, the need for more effective and durable protection, and constraints in manufacturing scaling.

As the field evolves, leveraging cutting-edge tools such as systems vaccinology, AI-driven design, and ex vivo human models will be essential in overcoming these barriers. In this article, we explore key trends shaping the future of vaccine development, highlight major challenges, and discuss how Genoskin’s ex vivo human skin models provide a powerful solution for accelerating non-clinical vaccine research.

The integration of high-throughput technologies and big data analytics is revolutionizing vaccine research. Multi-omics approaches—such as transcriptomics, proteomics, and metabolomics—enable a deeper understanding of immune responses at a cellular and molecular level. AI and machine learning algorithms further enhance vaccine design by predicting antigenic targets and optimizing formulations.¹

mRNA vaccines have revolutionized COVID-19 response and hold promise beyond the pandemic. Their adaptability enables rapid development, making them ideal for emerging variants and new diseases. mRNA technology is also being explored for cancer immunotherapies and mRNA-based therapeutics.²

Beyond mRNA, other innovative platforms are advancing vaccine science. Recombinant vaccines use genetic material from pathogens to produce antigens, enabling large-scale production. Compound vaccines combine multiple antigens for broader protection, while viral vector vaccines employ harmless viruses to deliver genetic material, as seen in Ebola and COVID-19 vaccines. These diverse approaches are expanding our vaccine development toolkit, shaping the future of disease prevention and treatment.

Speeding up vaccine development is critical for responding to emerging health threats, but it must be balanced with rigorous safety protocols. Strategies such as adaptive clinical trial designs, parallel regulatory reviews, and leveraging advanced preclinical models like ex vivo human skin platforms can significantly shorten development timelines while ensuring safety and efficacy. By integrating these innovative approaches, researchers can rapidly validate new vaccine candidates without cutting essential safety measures.

The emergence of personalized medicine is extending into vaccine development, with tailored immunizations being explored for infectious diseases and cancer immunotherapy. Advances in mRNA technology and synthetic biology enable the rapid design of individualized vaccines based on a person’s genetic and immune profile, potentially improving efficacy and reducing adverse reactions.³

New adjuvant formulations and alternative vaccine delivery methods are being developed to enhance immune responses while minimizing side effects. Innovations like microneedle patches⁴, lipid nanoparticles⁵, and intradermal delivery systems show promise in improving antigen uptake, ensuring sustained immunity, and facilitating global distribution.

As new technologies emerge, regulatory agencies must adapt to ensure safety and efficacy while expediting approvals. Frameworks for accelerated clinical trials and real-world data integration are being explored to facilitate the adoption of next-generation vaccines.⁶ Ethical concerns surrounding data privacy, genetic modification, and equitable vaccine access will also shape future policies.

Traditional animal models have long played a role in vaccine research, yet their ability to predict human immune responses remains limited. Species-specific immune variations often result in inconsistencies in efficacy and safety, slowing clinical translation.⁷

The accuracy of these models in mimicking human inflammatory responses is debated. While genetic differences between mice and humans are well-documented, variations in immunological history and infection exposure further complicate reproducibility.⁸ Advanced human-relevant models are needed to bridge this gap and improve vaccine development outcomes.

mRNA vaccines have revolutionized COVID-19 response and hold promise beyond the pandemic. Their adaptability enables rapid development, making them ideal for emerging variants and new diseases. mRNA technology is also being explored for cancer immunotherapies and mRNA-based therapeutics.²

Beyond mRNA, other innovative platforms are advancing vaccine science. Recombinant vaccines use genetic material from pathogens to produce antigens, enabling large-scale production. Compound vaccines combine multiple antigens for broader protection, while viral vector vaccines employ harmless viruses to deliver genetic material, as seen in Ebola and COVID-19 vaccines. These diverse approaches are expanding our vaccine development toolkit, shaping the future of disease prevention and treatment.

The global demand for vaccines necessitates efficient manufacturing and distribution strategies. Scaling up novel vaccine platforms—particularly those relying on lipid nanoparticles or mRNA synthesis—requires substantial investment in infrastructure and supply chain resilience.^9,10

Efforts to increase global manufacturing capacities have also focused on regional equity.¹¹ For instance, the World Health Organization is leading efforts to create an mRNA vaccine technology transfer hub in South Africa to increase mRNA vaccine production in low- and middle-income countries.¹²

Rapid viral evolution presents an ongoing challenge in vaccine durability. Variants of concern, as seen with SARS-CoV-2¹³, can evade immune recognition, necessitating continuous updates and booster strategies. Understanding cross-reactive immunity and broad-spectrum vaccine design will be essential for long-term protection.¹⁴

To bridge the translational gap between preclinical research and human trials, innovative models are needed. Genoskin’s ex vivo human skin platforms offer a powerful solution for vaccine testing by maintaining the physiological complexity of human skin in a controlled environment.

Vaccine research is increasingly prioritizing human-relevant models to reduce dependence on traditional animal testing. Cutting-edge technologies like ex vivo human skin models and organoids provide innovative alternatives, allowing for more precise evaluation of drug and vaccine efficacy and toxicity. By using bio-stabilized, immunocompetent human skin samples, these platforms generate high-quality human data early in development, improving translational success and accelerating progress toward safer, more effective vaccines.

Ex vivo human skin models provide an immunocompetent microenvironment that allows researchers to study localized immune activation post-injection. Unlike animal models, these systems retain native human antigen-presenting cells, mast cells, and other key immune players involved in vaccine response.¹⁵

• Assess local immune activation: By monitoring cytokine release and immune cell activation, researchers can assess vaccine-induced inflammation and immune responses in real human tissue.
• Understanding innate immune responses: Ex vivo models help evaluate how vaccines and adjuvants interact with skin-resident immune cells, leading to more informed vaccine formulation decisions.
• Deciphering vaccine mechanisms of action: Next-generation transcriptomics allow researchers to analyze cell-specific transcriptomic modulations post-vaccination and identify immune cells involved in mRNA vaccine uptake and response.
• Optimizing vaccine formulations and delivery methods: Testing intradermal and transdermal vaccine delivery approaches in human skin allows for optimization before clinical trials.

Regulatory agencies and industry leaders increasingly recognize the value of human-relevant models in vaccine research. Ex vivo platforms can support investigational new drug (IND) applications by providing mechanistic insights and safety data that complement traditional preclinical testing methods.

In line with ethical and scientific advancements, regulatory bodies and pharmacopeias are championing the 3Rs principles (Replacement, Reduction, and Refinement) in vaccine development and quality control.¹⁶ This progressive shift not only aligns with ethical considerations but also streamlines development timelines, reduces costs, and enhances translational accuracy for human applications.

The future of vaccine research is driven by innovation, from AI-powered design to personalized vaccines and novel delivery methods. However, overcoming preclinical limitations remains an important hurdle. Ex vivo human models and platforms such as VaxSkin® provide an innovative approach to accelerating vaccine development while improving human relevance.

As the field continues to evolve, integrating advanced preclinical models will be essential for designing safer, more effective vaccines. Explore how Genoskin’s solutions can support your vaccine research—contact us today to learn more.

1. David B. Olawade, Jennifer Teke, Oluwaseun Fapohunda, Kusal Weerasinghe, Sunday O. Usman, Abimbola O. Ige, Aanuoluwapo Clement David-Olawade, Leveraging artificial intelligence in vaccine development: A narrative review, Journal of Microbiological Methods, Volume 224, 2024, 106998, ISSN 0167-7012, https://doi.org/10.1016/j.mimet.2024.106998.
2. mRNA vaccines and treatments: beyond COVID-19
3. Poland GA, Ovsyannikova IG, Jacobson RM. Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther. 2008 Nov;8(11):1659-67. doi: 10.1517/14712598.8.11.1659. PMID: 18847302; PMCID: PMC2831634.
4. Nguyen TT, Oh Y, Kim Y, Shin Y, Baek SK, Park JH. Progress in microneedle array patch (MAP) for vaccine delivery. Hum Vaccin Immunother. 2021 Jan 2;17(1):316-327. doi: 10.1080/21645515.2020.1767997. Epub 2020 Jul 15. PMID: 32667239; PMCID: PMC7872046.
5. Swetha K, Kotla NG, Tunki L, Jayaraj A, Bhargava SK, Hu H, Bonam SR, Kurapati R. Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines. Vaccines (Basel). 2023 Mar 14;11(3):658. doi: 10.3390/vaccines11030658. PMID: 36992242; PMCID: PMC10059764.
6. Project NextGen
7. Emiliano Chiarot, Mariagrazia Pizza, Animal models in vaccinology: state of the art and future perspectives for an animal-free approach, Current Opinion in Microbiology, Volume 66, 2022, Pages 46-55, ISSN 1369-5274, https://doi.org/10.1016/j.mib.2021.11.014.
8. Herati RS, Wherry EJ. What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? Consideration of Strategies to Improve the Value of Animal Models. Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):a031583. doi: 10.1101/cshperspect.a031583. PMID: 28348037; PMCID: PMC5880169.
9. Ole Kristian Aars, Michael Clark, Nina Schwalbe, Increasing efficiency in vaccine Production: A primer for change, Vaccine: X, Volume 8, 2021, 100104, ISSN 2590-1362, https://doi.org/10.1016/j.jvacx.2021.100104.
10. Feddema JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM. Upscaling vaccine manufacturing capacity – key bottlenecks and lessons learned. Vaccine. 2023 Jul 5;41(30):4359-4368. doi: 10.1016/j.vaccine.2023.05.027. Epub 2023 Jun 3. PMID: 37277250; PMCID: PMC10239264.
11. Mukherjee S, Kalra K, Phelan AL (2023) Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries. PLOS Global Public Health 3(6): e0002098. https://doi.org/10.1371/journal.pgph.0002098
12. The mRNA vaccine technology transfer hub
13. Zhao, F., Zai, X., Zhang, Z. et al. Challenges and developments in universal vaccine design against SARS-CoV-2 variants. npj Vaccines 7, 167 (2022). https://doi.org/10.1038/s41541-022-00597-4
14. Gobeil, P., Pillet, S., Boulay, I. et al. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19. Nat Commun 13, 6905 (2022). https://doi.org/10.1038/s41467-022-34728-1
15. Scholaert M, Peries M, Braun E, et al. Multimodal profiling of biostabilized human skin modules reveals a coordinated ecosystem response to injected mRNA-1273 COVID-19 vaccine. Allergy. 2024; 79: 3341-3359. doi:10.1111/all.16273
16. Replacement, Reduction and Refinement of animal testing (3Rs): latest achievements – European Directorate for the Quality of Medicines & HealthCare